Скачать или смотреть The optimization of stem cell collection in HSCT

Christian Chabannon, MD, PhD, Institut Paoli Calmettes, Marseille, France, talks on the strategies used to optimize stem cell collection for hematopoietic stem cell transplantation (HSCT) and comments on how these methods are expected to evolve in the future. Prof. Chabannon explains that in the past 10 years, there has been little novelty in the products used to induce and improve stem cell mobilization. Stem cell mobilization is mainly used in the context of autologous stem cell transplantation and for allogeneic HSCT. Whilst in autologous transplantation plerixafor is widely used to collect stem cells, making mobilization failures a rare event, this drug has not yet been approved for allogeneic HSCT. Prof. Chabannon comments on clinical trials that have shown efficacy and safety in this context. Finally, he mentions several early experiments investigating new agents for stem cell mobilization, but predicts that the new generation of cellular therapies might interrupt their development. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.